

Development of activated natural killer (NK) cells mediated immunotherapy in cancer

Submission date 15/07/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 08/08/2008	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 16/08/2011	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Miss Hareum Lee

Contact details
Department of Life Sciences
Sookmyung Women's University
Hyochangwon-gil 52
Yongsan-gu
Seoul
Korea, South
140-742

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title
Research for the effect of biological response modifiers (BRMs) on natural killer (NK) cell cytotoxicity

Study objectives

Natural killer (NK) cells play an important role in innate immune response by destroying tumours and virus-infected cells without prior stimulation. Because of their attractive features, the application of NK cell-based immunotherapy has been extended to cancer treatment. This study investigates the function of biological response modifiers (BRMs) on NK cell cytotoxicity and the effect of NK cell mediated immunotherapy in cancer.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Samsung Medical Centre Institutional Review Board. Date of approval: 18/03/2008 (ref: 2008-03-038)

Study design

Single-centre, observational study

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Immunotherapy in cancer

Interventions

A blood sample will be obtained from each participant. A variety of BRMs (small synthetic peptides, interleukins, natural extracts) will be tested on the blood samples to measure their effect on NK cell cytotoxicity. This will be measured using established assays such as carboxyfluorescein diacetate succinimidylester (CFSE). The BRMs that show high levels of NK cell cytotoxicity will have the potential for use in cancer treatment.

Contact details of Principal Investigator:

Dr Daeho Cho

Department of Life Sciences

Sookmyung Women's University

Hyochangwon-gil 52

Yongsan-gu

Seoul, 140-742

Korea, South

Tel: +82 2 710 9416

Fax: +82 2 6359 6789

Email: cdhkor@sm.ac.kr

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

1. To find BRMs that lead to the highest levels of NK cell cytotoxicity in the treated blood samples
2. To find the optimum dose and duration of treatment with the BRMs found to elicit highest levels of NK cell cytotoxicity

Key secondary outcome(s)

Gene expression profiles associated with peripheral blood lymphocyte (PBL) cytotoxicity and related mechanisms in the blood samples.

Completion date

30/04/2010

Eligibility**Key inclusion criteria**

1. Healthy volunteers aged 18 years or older, both males and females
2. Written informed consent

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Aged less than 18 years
2. Those who do not speak Korean

Date of first enrolment

01/05/2008

Date of final enrolment

30/04/2010

Locations**Countries of recruitment**

Korea, South

Study participating centre
Department of Life Sciences
Seoul
Korea, South
140-742

Sponsor information

Organisation
Sookmyung Women's University (Korea, South)

ROR
<https://ror.org/00vvvt117>

Funder(s)

Funder type
Government

Funder Name
Korea Health Industry Development Institute (KHIDI) (ref: A080363)

Alternative Name(s)
KHIDI

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
Korea, South

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes